文献速递真菌感染

血液恶性肿瘤患者侵袭性曲霉病及三唑类耐药烟曲霉的流行病学:单中心回顾性队列研究

Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该单中心回顾性队列研究纳入2006至2012年接受AML或MDS化疗或异基因HSCT的432例患者,确诊或拟诊侵袭性曲霉病36例(8.3%,95%CI 6.0%-11.4%),其中12例基于烟曲霉培养阳性,2例检出三唑类耐药;另有13例无侵袭性曲霉病的患者标本中分离出烟曲霉,3例记录到三唑类耐药。作者认为高危患者中伏立康唑耐药侵袭性曲霉病的总体频率较低,但基于烟曲霉培养的低检出率可能低估了三唑类耐药率,PCR等替代诊断方法可能更有利于检出三唑类耐药烟曲霉所致的侵袭性曲霉病。

要点

  • 432例高危血液恶性肿瘤患者中确诊或拟诊侵袭性曲霉病36例(8.3%,95%CI 6.0%-11.4%)。
  • 12例基于烟曲霉培养阳性诊断,其中2例检出三唑类耐药。
  • 13例无侵袭性曲霉病的患者标本中分离出烟曲霉,3例记录到三唑类耐药。

核心结论

  • 高危患者中伏立康唑耐药侵袭性曲霉病的总体频率较低。
  • 基于烟曲霉培养的低检出率可能低估了三唑类耐药率。
  • PCR等替代诊断方法可能更有利于检出三唑类耐药烟曲霉所致的侵袭性曲霉病。

研究设计与样本

  • 单中心回顾性队列研究,纳入2006至2012年接受AML或MDS化疗或异基因HSCT的连续患者。
  • 共纳入432例患者,其中AML或MDS化疗182例(42.1%),异基因HSCT 250例(57.9%)。
  • 三唑类耐药通过VIPcheck™筛查方法检测,并通过EUCAST方法测定MIC确认。

主要发现

  • 确诊或拟诊侵袭性曲霉病36例(8.3%,95%CI 6.0%-11.4%)。
  • 36例中12例(33.3%)基于痰、支气管肺泡灌洗液或活检标本培养出烟曲霉,其中2例检出三唑类耐药。
  • 13例无确诊或拟诊侵袭性曲霉病的患者一个或多个标本中分离出烟曲霉。
  • 3例患者记录到三唑类耐药。
  • 伏立康唑耐药菌所致侵袭性曲霉病患者的生存率无法评估。

局限性

  • 伏立康唑耐药菌所致侵袭性曲霉病患者的生存率无法评估。
  • 基于烟曲霉培养的低检出率可能低估了三唑类耐药率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the epidemiology and clinical relevance of triazole resistance among patients undergoing treatment for haematological malignancies who are at risk of invasive aspergillosis (IA). METHODS: This was a retrospective cohort study for which the records of consecutive patients given chemotherapy for AML or myelodysplastic syndrome (MDS) or who had received an allogeneic HSCT from 2006 to 2012 were reviewed for IA. Triazole resistance was detected by the VIPcheck™ screening method and confirmed by determining the MIC by EUCAST methodology. RESULTS: A total of 432 patients were included, comprising 182 (42.1%) patients who had undergone chemotherapy for AML or MDS, and 250 (57.9%) patients who had undergone an allogeneic HSCT. Probable or proven IA was diagnosed in 36 cases (8.3%, 95% CI 6.0%-11.4%). Of these, 12 (33.3%) were based on recovery of Aspergillus fumigatus from sputum, bronchoalveolar lavage or biopsy, and triazole resistance was found in 2 instances. A. fumigatus was also recovered from one or more specimens from 13 patients without probable or proven IA. Triazole resistance was documented for three patients. The survival rate of patients with IA caused by voriconazole-resistant isolates could not be assessed. CONCLUSIONS: The overall frequency of voriconazole-resistant IA among patients at high risk was low. However, the rate of triazole resistance may have been underestimated by the low detection rate based on recovery of A. fumigatus. Alternative diagnostic tests, such as PCR-based assays, may prove better at detecting IA due to triazole-resistant A. fumigatus.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lestrade PP, van der Velden WJFM, Bouwman F, et al. Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study. J Antimicrob Chemother. 2018. PMID: 29394399. doi:10.1093/jac/dkx527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。